

2Q25 Regulation G Financial Reconciliations & Appendix



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)⁽¹⁾
(in thousands, except percentages)

	Three Months Ended		Six Months Ended	
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Research Models and Services				
Revenue	\$ 213,271	\$ 206,389	\$ 426,344	\$ 427,296
Operating income	35,786	29,948	79,391	73,097
Operating income as a % of revenue	16.8 %	14.5 %	18.6 %	17.1 %
Add back:				
Amortization related to acquisitions ⁽²⁾	10,674	7,357	23,361	17,645
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	—	174	14	337
Severance	3,299	494	3,528	1,034
Asset impairment	2,504	8,418	2,823	13,643
Site consolidation charges	1,616	1,310	2,492	2,931
Total non-GAAP adjustments to operating income	<u>\$ 18,093</u>	<u>\$ 17,753</u>	<u>\$ 32,218</u>	<u>\$ 35,590</u>
Operating income, excluding non-GAAP adjustments	\$ 53,879	\$ 47,701	\$ 111,609	\$ 108,687
Non-GAAP operating income as a % of revenue	25.3 %	23.1 %	26.2 %	25.4 %
Depreciation and amortization	\$ 19,710	\$ 16,538	\$ 41,471	\$ 34,661
Capital expenditures	\$ 3,640	\$ 9,313	\$ 10,926	\$ 29,357
Discovery and Safety Assessment				
Revenue	\$ 618,029	\$ 627,419	\$ 1,210,638	\$ 1,232,871
Operating income	122,781	138,376	216,733	253,215
Operating income as a % of revenue	19.9 %	22.1 %	17.9 %	20.5 %
Add back:				
Amortization related to acquisitions ⁽²⁾	18,212	20,298	36,383	38,894
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	1,287	5,591	2,348	5,783
Severance	237	2,429	5,216	7,913
Asset impairment	11,911	487	21,697	512
Site consolidation charges	3,928	850	6,705	1,832
Third-party legal and advisory costs ⁽⁴⁾	10,817	2,110	21,787	4,301
Total non-GAAP adjustments to operating income	<u>\$ 46,392</u>	<u>\$ 31,765</u>	<u>\$ 94,136</u>	<u>\$ 59,235</u>
Operating income, excluding non-GAAP adjustments	\$ 169,173	\$ 170,141	\$ 310,869	\$ 312,450
Non-GAAP operating income as a % of revenue	27.4 %	27.1 %	25.7 %	25.3 %
Depreciation and amortization	\$ 42,575	\$ 47,729	\$ 84,659	\$ 93,518
Capital expenditures	\$ 18,500	\$ 19,444	\$ 53,021	\$ 68,403
Manufacturing Solutions				
Revenue	\$ 200,835	\$ 192,309	\$ 379,321	\$ 377,510
Operating income	12,061	37,230	3,441	70,911
Operating income as a % of revenue	6.0 %	19.4 %	0.9 %	18.8 %
Add back:				
Amortization related to acquisitions ⁽²⁾	46,333	10,768	92,410	21,561
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	—	544	—	1,243
Severance	(383)	1,671	1,821	3,194
Asset impairment	6,157	25	6,358	25
Site consolidation charges	1,670	965	2,976	1,065
Total non-GAAP adjustments to operating income	<u>\$ 53,777</u>	<u>\$ 13,973</u>	<u>\$ 103,565</u>	<u>\$ 27,088</u>
Operating income, excluding non-GAAP adjustments	\$ 65,838	\$ 51,203	\$ 107,006	\$ 97,999
Non-GAAP operating income as a % of revenue	32.8 %	26.6 %	28.2 %	26.0 %
Depreciation and amortization	\$ 55,343	\$ 20,073	\$ 109,966	\$ 39,878
Capital expenditures	\$ 11,161	\$ 10,583	\$ 28,440	\$ 19,445

CONTINUED ON NEXT SLIDE

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)⁽¹⁾
(in thousands, except percentages)

	Three Months Ended		Six Months Ended	
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
CONTINUED FROM PREVIOUS SLIDE				
Unallocated Corporate Overhead	\$ (70,494)	\$ (53,902)	\$ (124,762)	\$ (119,594)
Add back:				
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	2,161	2,108	2,891	3,637
Severance	574	1,304	1,576	2,794
Asset impairment	184	—	184	—
Site consolidation charges	503	—	669	—
Third-party legal and advisory costs ⁽⁴⁾	6,376	—	6,376	—
Total non-GAAP adjustments to operating expense	<u>\$ 9,798</u>	<u>\$ 3,412</u>	<u>\$ 11,696</u>	<u>\$ 6,431</u>
Unallocated corporate overhead, excluding non-GAAP adjustments	\$ (60,696)	\$ (50,490)	\$ (113,066)	\$ (113,163)
Total				
Revenue	\$ 1,032,135	\$ 1,026,117	\$ 2,016,303	\$ 2,037,677
Operating income	100,134	151,652	174,803	277,629
Operating income as a % of revenue	9.7 %	14.8 %	8.7 %	13.6 %
Add back:				
Amortization related to acquisitions ⁽²⁾	75,219	38,423	152,154	78,100
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	3,448	8,417	5,253	11,000
Severance	3,727	5,898	12,141	14,935
Asset impairment	20,756	8,930	31,062	14,180
Site consolidation charges	7,717	3,125	12,842	5,828
Third-party legal and advisory costs ⁽⁴⁾	17,193	2,110	28,163	4,301
Total non-GAAP adjustments to operating income	<u>\$ 128,060</u>	<u>\$ 66,903</u>	<u>\$ 241,615</u>	<u>\$ 128,344</u>
Operating income, excluding non-GAAP adjustments	\$ 228,194	\$ 218,555	\$ 416,418	\$ 405,973
Non-GAAP operating income as a % of revenue	22.1 %	21.3 %	20.7 %	19.9 %
Depreciation and amortization	\$ 119,507	\$ 86,082	\$ 239,871	\$ 171,439
Capital expenditures	\$ 35,298	\$ 39,486	\$ 94,622	\$ 118,630

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

⁽²⁾ Amortization related to acquisitions for the three and six months ended June 28, 2025 includes \$35.5 million and \$71.0 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment.

⁽³⁾ These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements.

⁽⁴⁾ Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)⁽¹⁾
(in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Net income available to Charles River Laboratories International, Inc. common shareholders	\$ 52,326	\$ 89,988	\$ 77,795	\$ 157,317
Add back:				
Adjustment of redeemable noncontrolling interest ⁽²⁾	—	301	—	702
Incremental dividends attributable to noncontrolling interest holders ⁽³⁾	—	3,792	—	9,022
Non-GAAP adjustments to operating income ⁽⁴⁾	127,079	65,576	239,472	127,017
Venture capital and strategic equity investment (gains) losses, net	1,424	(902)	11,393	(6,664)
(Gain) loss on divestitures ⁽⁵⁾	—	—	(3,376)	658
Tax effect of non-GAAP adjustments:				
Non-cash tax provision related to international financing structure ⁽⁶⁾	—	871	—	1,212
Tax effect of the remaining non-GAAP adjustments	(26,837)	(14,687)	(52,182)	(26,715)
Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments	<u>\$ 153,992</u>	<u>\$ 144,939</u>	<u>\$ 273,102</u>	<u>\$ 262,549</u>
Weighted average shares outstanding - Basic	49,149	51,551	49,913	51,494
Effect of dilutive securities:				
Stock options, restricted stock units and performance share units	<u>167</u>	<u>295</u>	<u>176</u>	<u>316</u>
Weighted average shares outstanding - Diluted	<u>49,316</u>	<u>51,846</u>	<u>50,089</u>	<u>51,810</u>
Earnings per share attributable to common shareholders:				
Basic	\$ 1.06	\$ 1.75	\$ 1.56	\$ 3.06
Diluted	\$ 1.06	\$ 1.74	\$ 1.55	\$ 3.04
Basic, excluding non-GAAP adjustments	\$ 3.13	\$ 2.81	\$ 5.47	\$ 5.10
Diluted, excluding non-GAAP adjustments	\$ 3.12	\$ 2.80	\$ 5.45	\$ 5.07

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

⁽²⁾ This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest.

⁽³⁾ This amount represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024.

⁽⁴⁾ This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders.

⁽⁵⁾ The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site.

⁽⁶⁾ This amount relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP REVENUE GROWTH
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) ⁽¹⁾

Three Months Ended June 28, 2025	<u>Total CRL</u>	<u>RMS Segment</u>	<u>DSA Segment</u>	<u>MS Segment</u>
Revenue growth, reported	0.6 %	3.3 %	(1.5)%	4.4 %
(Increase) decrease due to foreign exchange	(1.2)%	(1.0)%	(1.1)%	(1.5)%
Impact of divestitures ⁽²⁾	0.1 %	— %	0.2 %	— %
Non-GAAP revenue growth, organic ⁽³⁾	<u>(0.5)%</u>	<u>2.3 %</u>	<u>(2.4)%</u>	<u>2.9 %</u>
Six Months Ended June 28, 2025	<u>Total CRL</u>	<u>RMS Segment</u>	<u>DSA Segment</u>	<u>MS Segment</u>
Revenue growth, reported	(1.0)%	(0.2)%	(1.8)%	0.5 %
(Increase) decrease due to foreign exchange	(0.2)%	— %	(0.2)%	(0.1)%
Impact of divestitures ⁽²⁾	0.1 %	— %	0.1 %	— %
Non-GAAP revenue growth, organic ⁽³⁾	<u>(1.1)%</u>	<u>(0.2)%</u>	<u>(1.9)%</u>	<u>0.4 %</u>

(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2) Impact of divestitures relates to the sale of a site within DSA.

(3) Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP REVENUE AND EARNINGS PER SHARE (EPS)
Guidance for the Twelve Months Ended December 27, 2025E

2025 GUIDANCE	CURRENT	PRIOR
Revenue growth/(decrease), reported	(2.5)% – (0.5)%	(5.5)% – (3.5)%
Impact of divestitures/(acquisitions), net	N/M	N/M
(Favorable)/unfavorable impact of foreign exchange	~(0.5)%	~1.0%
Revenue growth/(decrease), organic (1)	(3.0)% – (1.0)%	(4.5)% – (2.5)%
GAAP EPS estimate	\$4.25 – \$4.65	\$4.35 – \$4.85
Acquisition-related amortization and other acquisition- and integration-related costs (2)	~\$3.60	~\$3.50
Costs associated with restructuring actions (3)	~\$1.40	~\$1.00
Certain venture capital and other strategic investment losses/(gains), net (4)	~\$0.17	~\$0.15
Other items (5)	~\$0.50	~\$0.30
Non-GAAP EPS estimate	\$9.90 – \$10.30	\$9.30 – \$9.80

Footnotes to Guidance Table:

(1) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures, as well as foreign currency translation.

(2) These adjustments include amortization related to intangible assets, inclusive of the acceleration of amortization expense related to certain CDMO client relationships, as well as the purchase accounting step-up on inventory and certain long-term biological assets. In addition, these adjustments include some costs related to the evaluation and integration of acquisitions and divestitures.

(3) These adjustments primarily include site consolidation (including site transition costs), severance, impairment, and other costs related to the Company's restructuring actions.

(4) Certain venture capital and other strategic investment performance only includes recognized gains or losses on certain investments. The Company does not forecast the future performance of these investments.

(5) These items primarily relate to (i) certain third-party legal costs related to investigations by the U.S. government into the NHP supply chain related to our DSA segment and (ii) certain third-party advisory costs related to the Company entering into a Cooperation Agreement with a shareholder.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TAX RATE TO NON-GAAP TAX RATE (UNAUDITED) ⁽¹⁾
(in thousands)

	Three Months Ended			Six Months Ended	
	June 28, 2025	March 29, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Income before income taxes & noncontrolling interests	\$ 71,418	\$ 35,978	\$ 119,653	\$ 107,396	\$ 218,664
Add back:					
Amortization related to acquisitions ⁽²⁾	75,219	76,935	38,423	152,154	78,100
Acquisition, integration, and divestiture-related adjustments ⁽³⁾	3,448	1,805	8,417	5,253	11,000
Severance	3,727	8,414	5,898	12,141	14,935
Asset impairments	20,756	10,306	8,930	31,062	14,180
Site consolidation charges	7,717	5,125	3,125	12,842	5,828
Third-party legal costs and advisory costs ⁽⁴⁾	17,193	10,970	2,110	28,163	4,301
Venture capital and strategic equity investment (gains) losses, net	1,424	9,969	(902)	11,393	(6,664)
(Gain) loss on divestitures ⁽⁵⁾	—	(3,376)	—	(3,376)	658
Income before income taxes & noncontrolling interests, excluding specified charges (Non-GAAP)	<u>\$ 200,902</u>	<u>\$ 156,126</u>	<u>\$ 185,654</u>	<u>\$ 357,028</u>	<u>\$ 341,002</u>
Provision for income taxes (GAAP)	\$ 18,725	\$ 10,100	\$ 25,392	\$ 28,825	\$ 49,921
Non-cash tax benefit related to international financing structure ⁽⁶⁾	—	—	(871)	—	(1,212)
Tax effect of the remaining non-GAAP adjustments	26,837	25,345	14,687	52,182	26,715
Provision for income taxes (Non-GAAP)	<u>\$ 45,562</u>	<u>\$ 35,445</u>	<u>\$ 39,208</u>	<u>\$ 81,007</u>	<u>\$ 75,424</u>
Total rate (GAAP)	26.2 %	28.1 %	21.2 %	26.8 %	22.8 %
Total rate, excluding specified charges (Non-GAAP)	22.7 %	22.7 %	21.1 %	22.7 %	22.1 %

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

⁽²⁾ Amortization related to acquisitions for the three and six months ended June 28, 2025 includes \$35.5 million and \$71.0 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment.

⁽³⁾ These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements.

⁽⁴⁾ Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain.

⁽⁵⁾ The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site.

⁽⁶⁾ This amount relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GROSS/NET LEVERAGE RATIO, INCLUDING GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED) ⁽¹⁾
(dollars in thousands, except for per share data)

	June 28, 2025	March 29, 2025	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021	December 26, 2020
DEBT ⁽²⁾:							
Total Debt & Finance Leases	\$ 2,335,306	\$ 2,514,223	\$ 2,243,134	\$ 2,652,717	\$ 2,711,208	\$ 2,666,359	\$ 1,979,784
Plus: Other adjustments per credit agreement	26,130	50,220	49,311	33,265	13,431	37,244	2,328
Less: Unrestricted Cash and Cash Equivalents up to \$150M	(150,000)	(150,000)	(150,000)	(150,000)	(150,000)	(150,000)	—
Total Indebtedness per credit agreement	\$ 2,211,436	\$ 2,414,443	\$ 2,142,445	\$ 2,535,982	\$ 2,574,639	\$ 2,553,603	\$ 1,982,112
Less: Cash and cash equivalents (net of \$150M above)	(32,824)	(79,356)	(44,606)	(126,771)	(83,912)	(91,214)	(228,424)
Net Debt	\$ 2,178,612	\$ 2,335,087	\$ 2,097,839	\$ 2,409,211	\$ 2,490,727	\$ 2,462,389	\$ 1,753,688

	June 28, 2025	March 29, 2025	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021	December 26, 2020
ADJUSTED EBITDA ⁽²⁾:							
Net income (loss) available to Charles River Laboratories International, Inc. common shareholders	\$ (69,225)	\$ (31,563)	\$ 10,297	\$ 474,624	\$ 486,226	\$ 390,982	\$ 364,304
Adjustments:							
Adjust: Non-cash gains/losses of VC partnerships & strategic investments	37,853	36,791	20,627	(79,288)	35,498	66,004	—
Less: Aggregate non-cash amount of nonrecurring gains	—	—	—	—	(32,638)	(42,247)	(1,361)
Plus: Interest expense	116,369	119,171	126,288	136,710	108,870	107,224	76,825
Plus: Provision for income taxes	46,727	53,394	67,823	100,914	130,379	81,873	81,808
Plus: Depreciation and amortization	430,173	396,748	361,741	314,124	303,870	265,540	234,924
Plus: Non-cash nonrecurring losses	314,181	305,981	299,976	44,077	16,572	8,573	16,810
Plus: Non-cash stock-based compensation	66,751	66,288	69,891	72,048	73,617	71,461	56,341
Plus: Permitted acquisition-related costs	12,324	11,406	11,612	15,639	34,453	51,256	18,750
Plus: Pro forma EBITDA adjustments for permitted acquisitions	—	—	—	18,542	5,306	4,008	8
Adjusted EBITDA (per the calculation defined in compliance certificates)	\$ 955,153	\$ 958,216	\$ 968,255	\$ 1,097,390	\$ 1,162,153	\$ 1,004,675	\$ 848,408

	June 28, 2025	March 29, 2025	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021	December 26, 2020
LEVERAGE RATIO:							
Gross leverage ratio per credit agreement (total debt divided by adjusted EBITDA)	2.32	2.52	2.21	2.31	2.22	2.54	2.34
Net leverage ratio (net debt divided by adjusted EBITDA)	2.3	2.4	2.2	2.2	2.1	2.5	2.1

	June 28, 2025	March 29, 2025	December 28, 2024	December 30, 2023	December 31, 2022	December 25, 2021
INTEREST COVERAGE RATIO:						
Capital Expenditures	208,959	213,147	232,967	323,050	326,338	232,149
Cash Interest Expense	116,461	119,554	127,119	139,545	110,731	107,389
Interest Coverage ratio per the credit agreement (Adjusted EBITDA minus Capital Expenditures divided by cash interest expense)	6.41x	6.23x	5.78x	5.55x	7.55x	7.19x

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

⁽²⁾ Pursuant to the definition in its credit agreement dated December 13, 2024, the Company has defined its pro forma leverage ratio as total debt divided by adjusted EBITDA for the trailing-twelve-month period. The Company has defined interest coverage ratio as adjusted EBITDA for the trailing-twelve-month period less the aggregate amount of capital expenditures for the trailing-twelve-period; divided by the consolidated interest expense for the period of four consecutive fiscal quarters.

Total Debt represents third-party debt and financial lease obligations minus up to \$150M of unrestricted cash and cash equivalents. Adjusted EBITDA represents net income, prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), adjusted for interest, taxes, depreciation and amortization, and certain items that management believes are not reflective of the operational performance of the business. These adjustments include, but are not limited to, non-cash gains/loss on venture capital portfolios and strategic partnerships, acquisition and divestiture-related expenses including transaction and advisory costs; asset impairments; changes in fair value of contingent consideration obligations; employee stock compensation; historical EBITDA of companies acquired during the period; and other items identified by the company.

Total Debt and EBITDA have not been restated for periods prior to Q4 2024 for the most recent amendment or any previous amendments.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (UNAUDITED)⁽¹⁾
(in thousands)

	Three Months Ended		Six Months Ended	
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Net cash provided by operating activities	\$ 204,603	\$ 193,535	\$ 376,300	\$ 323,423
Less: Capital expenditures	(35,298)	(39,486)	(94,622)	(118,630)
Free cash flow	\$ 169,305	\$ 154,049	\$ 281,678	\$ 204,793

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) ⁽¹⁾
(in thousands, except percentages)

	Three Months Ended
	March 29, 2025
Unallocated Corporate Overhead	\$ (54,268)
Add back:	
Acquisition, integration, and divestiture-related adjustments ⁽²⁾	730
Severance	1,002
Site consolidation charges	166
Total non-GAAP adjustments to operating expense	\$ 1,898
Unallocated corporate overhead, excluding non-GAAP adjustments	\$ (52,370)

⁽¹⁾ Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

⁽²⁾ These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements.

CRL

LISTED

NYSE


charles river